Sonosemi
Developer of active vascular interventional medical devices, including intravascular lithotripsy (IVL) systems and intracardiac echocardiography (ICE) systems for coronary artery disease, peripheral vascular disease, and structural heart disease.
- CEO / Founder
- Liu Bin (刘斌)
- Team Size
- 51-200
- Stage
- Growth Stage
- Total Funding
- $100.0M
- Latest Round
- Series B
- Key Investors
- Tencent Investment; Eight Roads (斯道资本); Yahui Investment (雅惠投资); Yuexiu Industrial Fund (越秀产业基金); CCB Equity (建信股权); Cornerstone Capital (基石资本); Furong Investment (复容投资); Ruijian Capital (睿笕资本); Jiuzhixinfei (久知心飞)
Technology & Products
Key Products
LiqMagic C14 Coronary IVL System (coronary intravascular lithotripsy); LiqMagic P18 Peripheral IVL System (peripheral intravascular lithotripsy); DynaSight ICE System (intracardiac echocardiography); Coronary Scoring Balloon Dilatation Catheter; IVUS System (intravascular ultrasound)
Technological Advantage
Proprietary ultrasound transducer and medical sensor chip technology; first domestic ICE system with 100% domestic core components; integrated therapeutic + diagnostic platform strategy; strong regulatory track record with multiple NMPA approvals through innovative device green channel
Differentiation
Value Proposition
Domestic Chinese alternative to global medical device leaders in active vascular interventional devices, with proprietary IVL and ICE technologies, offering cost-effective solutions for coronary and peripheral artery calcification treatment and cardiac imaging.
How They Differentiate
Proprietary ultrasound and medical sensor platform technology; early mover in domestic IVL and ICE markets; 100+ patent applications including 50+ invention patents; strategic distribution partnership with MicroPort Endovastec for peripheral IVL; backed by Tencent and top-tier healthcare VCs.
Market & Competition
Target Customers
Hospitals and interventional cardiologists treating coronary artery disease, peripheral artery disease, and structural heart disease; interventional radiology departments
Industry Verticals
Medical Devices; Interventional Cardiology; Peripheral Vascular Intervention; Structural Heart Disease; Electrophysiology
Competitors
Shockwave Medical (US/Johnson & Johnson); Lepu Medical (乐普医疗); Huihe Medical (汇禾医疗); Puchuang Medical (谱创医疗)
Growth & Milestones
Major Milestones
2020-04: Company founded; 2021-06: Pre-A round (~¥100M); 2022-04: A round (¥100Ms); 2023-10: Coronary IVL system NMPA approved (first domestic); 2023-10: B round (>¥200M); 2024-07: ICE system NMPA approved (first domestic complete system); 2024-12: Peripheral IVL system NMPA approved; 2025-02: Distribution partnership with MicroPort Endovastec; 2025-10: Recognized as National Specialized & New Little Giant Enterprise; 2025-12: IVUS system NMPA approved; 2026-01: Coronary scoring balloon catheter NMPA approved; 2026-07: B+ round (¥100Ms)
Notable Customers
Multiple top-tier Chinese hospitals including Zhongshan Hospital affiliated with Fudan University, Tianjin Medical University General Hospital, and others (products entering hospital systems post-NMPA approval)